JEDD D WOLCHOK, MD
Osteopathic Medicine at York Ave, New York, NY

2002015, Oct 17, 2002

Nov 27, 2001

09/996128

Alan Houghton - New York NY, US
Philip Bergman - Tarrytown NY, US
Jedd Wolchok - New York NY, US

A61K039/00, C12N009/64

424/185100, 435/226000

Melanoma can be treated in a mammalian subject by administering to the subject an immunologically-effective amount of a xenogeneic melanoma-associated differentiation antigen. For example, genetic immunization with a plasmid containing a sequence encoding human gp75 has been shown to be effective in treatment of dogs with melanoma.

8021666, Sep 20, 2011

Oct 31, 2002

10/285874

Maria Lia Palomba - New York NY, US
Alan Houghton - New York NY, US
Jedd Wolchok - New York NY, US
David A. Scheinberg - New York NY, US
Wendy K. Roberts - New York NY, US

Sloan-Kettering Institute for Cancer Research - New York NY

C07K 14/705, C07K 14/435, A61K 39/00

4241851, 424450, 424 851

Tolerance of the immune system for endogenous CD20 can be overcome and an immune response stimulated by administration of xenogeneic or xenoexpressed CD20 antigen. For example, mouse CD20, or antigenically-effective portions thereof, can be used to stimulate an immune response to the corresponding differentiation antigen in a human subject. Administration of xenogeneic antigens in accordance with the invention results in an effective immunity against CD20 expressed by the cancer in the treated individual, thus providing a therapeutic approach to the treatment of lymphomas and leukemia expressing CD20.

2012012, May 24, 2012

Apr 8, 2010

13/263369

Jedd D. Wolchok - New York NY, US
Francesca Avogadri - New York NY, US
Robert A. Olmsted - Chapel Hill NC, US
Maureen Maughan - Chapel Hill NC, US

A61K 39/00, A61P 35/00, A61P 35/04, A61P 37/04

4241991

The immune response to melanoma cells and tumors can be induced or significantly increased by administering to a subject a pharmaceutical composition comprising alphavirus particles, especially Venezuelan equine encephalitis virus replicon particles, which express the melanoma antigen dopachrome tautomerase (DCT, TRP2) in cells of the subject, with the result of tumor regression and/or inhibition of metastasis of a melanoma subject, or a decreased risk of the occurrence or recurrence of melanoma and/or decreased severity of melanoma in a subject not suffering from melanoma at the time of administration. The pharmaceutical composition described herein can be used in conjunction with other therapeutic agents, it can be administered on more than one occasion and it can be combined with administrations of other compositions such as protein or other immunogenic compositions, and/or adjuvants, with beneficial effects to the human or animal subject to which it has been administered.